- Home
- VNDA vs AVIR Comparison
VNDA vs AVIR Comparison
Compare VNDA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- AVIR
- Stock Information
- Founded
- VNDA 2002
- AVIR 2012
- Country
- VNDA United States
- AVIR United States
- Employees
- VNDA N/A
- AVIR N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- VNDA Health Care
- AVIR Health Care
- Exchange
- VNDA Nasdaq
- AVIR Nasdaq
- Market Cap
- VNDA 275.2M
- AVIR 273.0M
- IPO Year
- VNDA 2006
- AVIR 2020
- Fundamental
- Price
- VNDA $4.19
- AVIR $3.47
- Analyst Decision
- VNDA Strong Buy
- AVIR Hold
- Analyst Count
- VNDA 3
- AVIR 1
- Target Price
- VNDA $15.33
- AVIR $6.00
- AVG Volume (30 Days)
- VNDA 559.3K
- AVIR 392.1K
- Earning Date
- VNDA 07-31-2025
- AVIR 08-07-2025
- Dividend Yield
- VNDA N/A
- AVIR N/A
- EPS Growth
- VNDA N/A
- AVIR N/A
- EPS
- VNDA N/A
- AVIR N/A
- Revenue
- VNDA $203,467,000.00
- AVIR N/A
- Revenue This Year
- VNDA $16.86
- AVIR N/A
- Revenue Next Year
- VNDA $39.78
- AVIR N/A
- P/E Ratio
- VNDA N/A
- AVIR N/A
- Revenue Growth
- VNDA 3.18
- AVIR N/A
- 52 Week Low
- VNDA $3.81
- AVIR $2.46
- 52 Week High
- VNDA $5.97
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- VNDA 32.22
- AVIR 46.31
- Support Level
- VNDA $4.60
- AVIR $3.36
- Resistance Level
- VNDA $4.89
- AVIR $3.97
- Average True Range (ATR)
- VNDA 0.17
- AVIR 0.19
- MACD
- VNDA -0.07
- AVIR -0.02
- Stochastic Oscillator
- VNDA 3.66
- AVIR 16.67
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).